100% of patients with MEN1 syndrome and 9.4% patients with non-MEN1 showed immunohistochemical nuclear menin loss in one or more tumors (Fig. 1A, B, Table 2 and Supplemental Table S1, Supplemental Digital Content 3, http://links.lww.com/PAS/B545; patient characteristics and consensus menin immunohistochemistry scores). This evidence concerns the gene MEN1 and multiple endocrine neoplasia type 1.